- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
US Bioservices Announces Wins in Three Strategic Areas
US Bioservices, an independent pharmacy and a part of AmerisourceBergen, announced that 2017 was a record-breaking year for new business wins in three strategic areas-oncology, rare and orphan, and specialty infusion. US Bioservices received access to 28 new products in 2017, including 10 oncology products and three rare and orphan therapies.
US Bioservices’ portfolio offers:
- Specialty Infusion: US Bioservices has more than 25 years of experience providing specialty infusion therapies, including IV drugs, and self-administered infusion and injection medications, to patients nationwide. US Bioservices offers personalized clinical support, including self-infusion training, in-home infusion nursing services and 24/7 access to clinical support.
- Oncology: With more than 80 members, US Bioservices’ Oncology Patient Support Team provides clinical care that is specific to the patient’s needs, conditions, and therapies.
- Rare & Orphan: US Bioservices’ depth of experience supporting rare and orphan programs, combined with AmerisourceBergen’s Signature® commercialization solutions, provide a range of program and partnership options that can be tailored to maximize results.
Through comprehensive technology systems, US Bioservices’ manufacturer partners get a transparent view into the therapy experience.
US Bioservices leverages resources provided by AmerisourceBergen companies, including Lash Group for patient support services; ION Solutions and Oncology Support for their connections to community oncology providers, and ICS and ASD Healthcare for rare and orphan logistics and distribution.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
